DE4129932A1 - Screening-verfahren und seine anwendung - Google Patents
Screening-verfahren und seine anwendungInfo
- Publication number
- DE4129932A1 DE4129932A1 DE4129932A DE4129932A DE4129932A1 DE 4129932 A1 DE4129932 A1 DE 4129932A1 DE 4129932 A DE4129932 A DE 4129932A DE 4129932 A DE4129932 A DE 4129932A DE 4129932 A1 DE4129932 A1 DE 4129932A1
- Authority
- DE
- Germany
- Prior art keywords
- dhea
- amount
- body fluid
- subject
- progression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims description 18
- 238000012216 screening Methods 0.000 title 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims description 52
- 210000001124 body fluid Anatomy 0.000 claims description 11
- 239000010839 body fluid Substances 0.000 claims description 11
- 210000002966 serum Anatomy 0.000 claims description 8
- 208000031886 HIV Infections Diseases 0.000 claims description 7
- 208000037357 HIV infectious disease Diseases 0.000 claims description 7
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 7
- 230000028327 secretion Effects 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 5
- 230000000984 immunochemical effect Effects 0.000 claims description 5
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000012790 confirmation Methods 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 41
- 229960002847 prasterone Drugs 0.000 description 41
- 208000030507 AIDS Diseases 0.000 description 16
- 239000000523 sample Substances 0.000 description 10
- 238000003018 immunoassay Methods 0.000 description 7
- 229940072417 peroxidase Drugs 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 102000003992 Peroxidases Human genes 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 108040007629 peroxidase activity proteins Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 238000005534 hematocrit Methods 0.000 description 4
- 239000011049 pearl Substances 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229950009829 prasterone sulfate Drugs 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 206010001513 AIDS related complex Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 230000009189 diving Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 230000000652 homosexual effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010027044 HIV Core Protein p24 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000005074 Retroviridae Infections Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- -1 diving sticks Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005184 men's health Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 208000010648 susceptibility to HIV infection Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE326690A IE63418B1 (en) | 1990-09-10 | 1990-09-10 | Progression risk of HIV by assay of dehydroepiandrosterone in body fluid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE4129932A1 true DE4129932A1 (de) | 1992-03-12 |
Family
ID=11038235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE4129932A Withdrawn DE4129932A1 (de) | 1990-09-10 | 1991-09-09 | Screening-verfahren und seine anwendung |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JPH04351964A (enrdf_load_stackoverflow) |
| DE (1) | DE4129932A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2666657A1 (enrdf_load_stackoverflow) |
| GB (1) | GB2249833B (enrdf_load_stackoverflow) |
| IE (1) | IE63418B1 (enrdf_load_stackoverflow) |
| IT (1) | IT1255009B (enrdf_load_stackoverflow) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4230684A (en) * | 1978-03-16 | 1980-10-28 | Cornell Research Foundation, Inc. | Method for determining steroids in human body liquids |
| NL194728C (nl) * | 1987-04-16 | 2003-01-07 | Hollis Eden Pharmaceuticals | Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan. |
| WO1990008959A1 (en) * | 1989-02-01 | 1990-08-09 | E.I. Du Pont De Nemours And Company | HIV p17 ASSAYS FOR MONITORING DEVELOPMENT OF AIDS |
| JPH02213766A (ja) * | 1989-02-15 | 1990-08-24 | Mochida Pharmaceut Co Ltd | 免疫測定用試薬および免疫測定器具 |
-
1990
- 1990-09-10 IE IE326690A patent/IE63418B1/en not_active IP Right Cessation
-
1991
- 1991-09-09 DE DE4129932A patent/DE4129932A1/de not_active Withdrawn
- 1991-09-09 IT ITMI912378A patent/IT1255009B/it active IP Right Grant
- 1991-09-09 JP JP3307281A patent/JPH04351964A/ja active Pending
- 1991-09-09 FR FR9111118A patent/FR2666657A1/fr active Granted
- 1991-09-09 GB GB9119256A patent/GB2249833B/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH04351964A (ja) | 1992-12-07 |
| IE63418B1 (en) | 1995-04-19 |
| ITMI912378A0 (it) | 1991-09-09 |
| FR2666657B1 (enrdf_load_stackoverflow) | 1997-02-21 |
| IT1255009B (it) | 1995-10-11 |
| ITMI912378A1 (it) | 1993-03-09 |
| GB2249833A (en) | 1992-05-20 |
| GB2249833B (en) | 1994-09-07 |
| GB9119256D0 (en) | 1991-10-23 |
| FR2666657A1 (fr) | 1992-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68924878T2 (de) | Bestimmung eines felinen pathogen-specifischen Antikörpers und eines felinen pathogenen Antigens in einem Immuntest. | |
| DE69306804T2 (de) | Immunologischer test auf festphase | |
| DE69923715T2 (de) | Messung von analyten in vollblut | |
| DE68922243T2 (de) | Immuntest für HIV-1-Antigene unter Benutzung von F(AB')2-Fragmenten als Sonde. | |
| AU2003284187B2 (en) | Inflammatory bowel disease and irritable bowel syndrome IBD-first chek diagnostic panel | |
| US5480776A (en) | Method for prediction of premature labor | |
| DE69622696T2 (de) | Zellzählung durch einen immunoassay | |
| US5514557A (en) | Method and kit for detecting antibodies specific for HLA and/or platelet glycoproteins | |
| DE60317931T2 (de) | Cvd-assay | |
| DE69027882T2 (de) | Messung der Reaktivität von Lymphozyten gegenüber spezifischen Antigenen im Blut | |
| DE102004041659A1 (de) | Testvorrichtung für die in vitro Diagnostik von Multianalyt-Tests und deren Verwendung | |
| Usui et al. | Serum uromodulin is a novel renal function marker in the Japanese population | |
| WO2004040311A1 (de) | Mittel und verfahren zur diagnose einer treponemainfektion | |
| DE19920704C1 (de) | Verwendung eines gegen Harn-Trypsin-Inhibitors gerichteten Antikörpers für die Diagnose des Ausbruchs von AIDS | |
| Toftager-Larsen et al. | Reactivity of amniotic fluid alpha-fetoprotein with concanavalin A in relation to gestational age: clinical implications. | |
| EP1318402B1 (de) | Verfahren zur Diagnose von Sepsis unter Bestimmung von CA 125 | |
| EP0809805B1 (de) | Verwendung von polyklonalen humanen anti-htg-autoantikörpern als reagenz für die klinische diagnostik von schilddrüsen-autoimmunerkrankungen sowie reagenziensatz für eine bestimmung von anti-htg-autoantikörpern in patientenseren | |
| KR100976327B1 (ko) | 소변 내의 인간 융모 생성샘 자극호르몬 농도 준 정량분석검출방법 및 그 검출기구 | |
| DE68907365T2 (de) | Verfahren zur Bestimmung des Vorhandenseins leichter Ketten in Urinproben, Komplex von Vorbereitungen zur Erledigung des Verfahrens und damit verbundenes Reagenz. | |
| DE4129932A1 (de) | Screening-verfahren und seine anwendung | |
| Toriyabe et al. | Maternal cytomegalovirus antibodies during early and late (persistent) phases after primary cytomegalovirus infection during pregnancy: An observational study | |
| EP2483418B1 (en) | A modified method of agglutination to detect infections caused by microorganisms | |
| DE69110067T2 (de) | Monoklonale Antikörper gegen nicht-A 1C glykosyliertes Hämoglobin. | |
| Buamah et al. | Concanavalin A binding of alpha-fetoprotein in amniotic fluid as an aid in the diagnosis of neural tube defects. | |
| DE69308825T2 (de) | Verfahren zur bestimmung von autoantikörpern in biologischen flüssigkeiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8141 | Disposal/no request for examination |